Henry Ford Health

Henry Ford Health Scholarly Commons
Neurosurgery Articles

Neurosurgery

8-1-2016

Application of morphometric analysis to patients with lung cancer
metastasis to the spine: a clinical study
Hesham M. Zakaria
Henry Ford Health, hzakari1@hfhs.org

Azam Basheer
Henry Ford Health, abashee1@hfhs.org

David Boyce-Fappiano
Henry Ford Health, dboyce1@hfhs.org

Erinma Elibe
Henry Ford Health, EELIBE1@hfhs.org

Lonni Schultz
Henry Ford Health, lschult1@hfhs.org

See next page for additional authors

Follow this and additional works at: https://scholarlycommons.henryford.com/neurosurgery_articles

Recommended Citation
Zakaria HM, Basheer A, Boyce-Fappiano D, Elibe E, Schultz L, Lee I, Siddiqui F, Griffith B, and Chang V.
Application of morphometric analysis to patients with lung cancer metastasis to the spine: a clinical
study. Neurosurg Focus 2016; 41(2):E12.

This Article is brought to you for free and open access by the Neurosurgery at Henry Ford Health Scholarly
Commons. It has been accepted for inclusion in Neurosurgery Articles by an authorized administrator of Henry
Ford Health Scholarly Commons.

Authors
Hesham M. Zakaria, Azam Basheer, David Boyce-Fappiano, Erinma Elibe, Lonni Schultz, Ian Lee, Farzan
Siddiqui, Brent Griffith, and Victor Chang

This article is available at Henry Ford Health Scholarly Commons: https://scholarlycommons.henryford.com/
neurosurgery_articles/247

neurosurgical

focus

Neurosurg Focus 41 (2):E12, 2016

Application of morphometric analysis to patients with
lung cancer metastasis to the spine: a clinical study
Hesham Mostafa Zakaria, MD,1 Azam Basheer, MD,1 David Boyce-Fappiano, BS,2
Erinma Elibe, BS,2 Lonni Schultz, PhD,3 Ian Lee, MD,1 Farzan Siddiqui, MD, PhD,2
Brent Griffith, MD,4 and Victor Chang, MD1
Departments of 1Neurosurgery, 2Radiation Oncology, 3Public Health Sciences, and 4Radiology, Neuroscience Institute, Henry
Ford Health System, Detroit, Michigan

Objective Predicting the survival rate for patients with cancer is currently performed using the TNM Classification of
Malignant Tumors (TNM). Identifying accurate prognostic markers of survival would allow better treatment stratification
between more aggressive treatment strategies or palliation. This is especially relevant for patients with spinal metastases, who all have identical TNM staging and whose surgical decision-making is potentially complex. Analytical morphometrics quantifies patient frailty by measuring lean muscle mass and can predict risk for postoperative morbidity after
lumbar spine surgery. This study evaluates whether morphometrics can be predictive of survival in patients with spinal
metastases.
Methods Utilizing a retrospective registry of patients with spinal metastases who had undergone stereotactic body
radiation therapy, the authors identified patients with primary lung cancer. Morphometric measurements were taken of
the psoas muscle using CT of the lumbar spine. Additional morphometrics were taken of the L-4 vertebral body. Patients
were stratified into tertiles based on psoas muscle area. The primary outcome measure was overall survival, which was
measured from the date of the patient’s CT scan to date of death.
Results A total of 168 patients were identified, with 54% male and 54% having multiple-level metastases. The median
survival for all patients was 185.5 days (95% confidence interval [CI] 146–228 days). Survival was not associated with
age, sex, or the number of levels of metastasis. Patients in the smallest tertile for the left psoas area had significantly
shorter survival compared with a combination of the other two tertiles: 139 days versus 222 days, respectively, hazard
ratio (HR) 1.47, 95% CI 1.06–2.04, p = 0.007. Total psoas tertiles were not predictive of mortality, but patients whose total
psoas size was below the median size had significantly shorter survival compared with those greater than the median
size: 146 days versus 253.5 days, respectively, HR 1.43, 95% CI 1.05–1.94, p = 0.025. To try to differentiate small body
habitus from frailty, the ratio of psoas muscle area to vertebral body area was calculated. Total psoas size became predictive of mortality when normalized to vertebral body ratio, with patients in the lowest tertile having significantly shorter
survival (p = 0.017). Left psoas to vertebral body ratio was also predictive of mortality in patients within the lowest tertile
(p = 0.021). Right psoas size was not predictive of mortality in any calculations.
Conclusions In patients with lung cancer metastases to the spine, morphometric analysis of psoas muscle and vertebral body size can be used to identify patients who are at risk for shorter survival. This information should be used to
select patients who are appropriate candidates for surgery and for the tailoring of oncological treatment regimens.
http://thejns.org/doi/abs/10.3171/2016.5.FOCUS16152

P
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atient frailty has been defined as a decreased reserve

and resistance to stressors, with decline across multiple physiological systems, and is a common end
point in human senescence.12,43 For a surgeon, the clinical appreciation of a frail patient is important, as a recent

body of literature has shown that frailty can predict morbidity and mortality after general, vascular, transplant, and
neurological surgery.6,17,28,33,56,57 Unfortunately, measuring
human frailty is subjective, burdensome, and impractical
in most clinical settings.2,33,57 Therefore, surrogate mark-

Abbreviations CI = confidence interval; HR = hazard ratio; TNM = TNM Classification of Malignant Tumors.
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ers of frailty, namely sarcopenia, have been successfully
used to predict postoperative morbidity and mortality following major surgery,9,10,17,28,40,46,56 including lumbar spine
surgery.57 Morphometrics is the measurement of patient
attributes that are indicative of sarcopenia and, by extension, frailty.
In terms of oncological surgery, the observation has
consistently been that patients who are sarcopenic not
only have increased rates of postoperative morbidity and
mortality, but also have shorter progression-free survival.19,23,37,46 The relationship between increased muscle
mass and disease-free survival has even been observed in
oncological patients who have not undergone any cancer
surgery.13,16,24,38,44,50,55 This is a notable observation, as current methodologies for predicting oncological outcomes
rely solely on histological grade of the malignancy and its
TNM Classification of Malignant Tumors (TNM). Identifying more accurate and specific markers of survival
would enable oncologists to discern which patients are appropriate candidates for a particular treatment, be it chemotherapy, radiation, surgery, or palliation.
In this study, we applied morphometric analysis of psoas muscle size to predict oncological outcomes in patients
who have had lung cancer metastases to the spine. In our
previous work, we identified patients who were at higher
risk of postoperative morbidity after lumbar spine surgery
by using the psoas area as a marker for sarcopenia.57 Our
hypothesis is that patients with lung cancer metastasis to
the spine will have shorter survival if they have less lean
muscle mass as measured by the psoas area.

Methods

Data Acquisition
This study was approved by the Henry Ford Hospital
Institutional Review Board. Using a retrospective registry
of patients with spinal metastases from 2002 to 2012 who
had undergone stereotactic body radiation therapy, we reviewed and identified a population of patients diagnosed
with primary lung cancer. This review included all histological subtypes of lung cancer. Additional treatments
such as radiation therapy or chemotherapy were inconsistently documented and therefore not included in data
acquisition. It should be noted, however, that most patients
with lung cancer would have received radiation therapy to
the primary site with some form of chemotherapy.
Morphometric Analysis
The full extent of our methodology for morphometric
analysis has been described previously.57 Briefly, morphometric measurements were taken of the psoas muscle at
the L-4 level, and a Philips ePACS viewer was used to
measure the circumference (in cm2) of each patient’s
psoas muscles. In addition, the L-4 vertebral body area
was measured and recorded in similar fashion. Measurements were made using the patient’s most recent CT scan
of the lumbar area. Psoas muscle sizes were divided into
tertiles according to total psoas area. Because the psoas
measurements were dependent on sex, the tertiles for left,
right, and total psoas were computed within the male and
female cohorts separately using different cutoff points. In
2

addition, the ratio of left, right, and total psoas area to the
vertebral body area was considered. Tertiles were computed for these new variables using different cutoff points
for males and females. Besides the tertile cutoff points, the
median cutoff point was also investigated.
In addition to absolute psoas size, we also attempted to
normalize psoas size based on each individual patient’s
stature. Intuitively, patients with smaller stature will tend
to have smaller psoas sizes. As a result, these patients
would not necessarily be sarcopenic nor at risk for shorter
survival. Our method of normalization of psoas muscle
size with body habitus consisted of calculating the ratio
of psoas muscle area to vertebral body area as a separate
variable for morphometric analysis. The primary outcome
measure was overall survival, which was measured from
the date of the patient’s scan to date of death. For patients
who were still alive at the time of analysis, survival was
calculated to the most recent documented follow-up evaluation.
Statistical Analysis
The median survival in days along with the corresponding 95% confidence interval (CI) was computed for all patients, as well as subsets of interest. Cox proportional hazards regression analyses were done to estimate the hazard
ratios (HRs) and test for differences in the variables of
interest. All testing was done at the 0.05 level. The statistical program SAS (version 9.4, SAS Institute) was used for
data analysis.

Results

There were 168 patients with spinal metastases from
lung cancer identified and included in this study. There
was 1 person without a right and total psoas measurement
because of the location of the tumor. Patient demographics can be found in Table 1. The average age (± SD) at the
time of CT scan was 65.3 ± 11.3 years, with a range from
33 to 97 years old. Ninety (54%) of the patients were male.
There were 78 patients (46%) with single-level metastases
and 90 (54%) with multiple-level metastases. There were
24 patients (14.3%) treated surgically in this series, with 6
(3.6%) undergoing instrumentation.
The median survival for all patients was 185.5 days
(95% CI 146–228 days). The associations of overall survival with age, sex, and the number of levels were not significant (Table 2). Comparisons of psoas size with survival
can be found in Table 3. When considering the total and
mean psoas tertiles, no significant differences in survival
were detected. However, the difference between patients
above and below the median of total psoas size and the
median of mean psoas size was significant, with patients
below the median having shorter survival (HR 1.43, p =
0.025 for total psoas size; HR 1.42, p = 0.026 for mean
psoas size). The Kaplan-Meier survival curves for this
data set provide a visual representation of the differences
in survival between these two groups (Fig. 1). Using the
left psoas only, patients in the lowest tertile (smallest psoas
size) had significantly shorter survival (median 139 days)
as compared with the middle (median 164 days, p = 0.038)
and highest (median 263 days, p = 0.011) tertiles. Survival
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TABLE 1. Patient demographics
Variable
Age (yrs)
Mean (SD)
Median (range)
Sex (%)
Male
Female
Race (%)
Caucasian
African American
Other
Not available
No. of levels treated (%)
1
2
3
4
5
6
Target volume in ml (%)*
Mean (SD)
Median (range)

TABLE 2. Overall survival and patient demographics
Value

Variable
Age
Sex
Male
Female
No. of levels
Single
Multiple

65.3 (11.3)
64 (33–97)
90 (54)
78 (46)
104 (62)
52 (31)
7 (4)
5 (3)
78 (46)
55 (33)
23 (14)
9 (5)
2 (1)
1 (0.6)
51.7 (39.3)
41.3 (0.565–209)

* In 143 patients.

of the lowest tertile was also significantly decreased when
compared with a combination of the other two tertiles,
139 days versus 222 days, respectively (p = 0.007). The
Kaplan-Meier survival curve for morphometrics based on
left psoas size is shown in Fig. 2. No significant differences were detected for the right psoas, using both tertile
and median cutoff points.
We also performed a similar analysis using values for
psoas size that were normalized for patient size by calculating a ratio of psoas muscle area to vertebral body
area (Table 4). When applying this ratio to total psoas
size, patients in the lowest tertile had statistically significant shorter survival as compared with the combination
of the other two tertiles (HR 1.49, 95% CI 1.07–2.07, p =
0.017). This normalization increased the sensitivity of our
morphometric analysis, as total psoas size tertiles without
normalization to vertebral body size did not show any statistically significant differences in survival (Table 2). The
Kaplan-Meier survival curves of total psoas size to vertebral body ratio are shown in Fig. 3. Similar results were
found for the ratio of left psoas size to vertebral body size,
as patients in the lowest tertile had significantly shorter
survival than a combination of the other two tertiles (HR
1.47, 95% CI 1.06–2.04, p = 0.021). No significant differences were detected for the ratio of right psoas size to vertebral body size.

Discussion

Since the publication of Patchell et al.’s seminal study
on surgical treatment of patients with spinal metasta-

Median Days of
Survival (95% CI)

HR (95% CI)

p Value

(Increase over 10 yrs)

0.92 (0.79–1.06)

0.234

90
78

188.5 (138–273)
179.5 (124–222)

Reference
1.11 (0.81–1.52)

0.505

78
90

183 (132–254)
185.5 (133–230)

Reference
1.14 (0.84–1.55)

0.412

N

ses,39 there has been an interest in spinal oncology as a
subspecialty and subsequently a growing body of literature regarding outcomes on the subject.4,5,20,27,42 Surgical
decision-making for this population can be challenging.
While surgery can improve overall survival and neurological outcome, and provide pain control, these procedures
delay cancer treatments (chemotherapy and radiation) and
are resource intensive.3,14,18,21,22,51 Surgical risk is also high,
with postoperative morbidity as high as 76%,7 which may
diminish any benefit of surgery and hasten patient demise.
Several authors have reported different classification
schemes attached to surgical decision-making algorithms
to treat the patient with spinal metastasis in general.11,26,
45,52,53
However, these scoring systems have a limited prognostic capability.14,41,49 With continued refinements to surgical technique as well as advances in implant technology, surgeons are able to undertake increasingly ambitious
resections followed by complex reconstructions.1,25,35 An
objective assessment of fitness for surgery would provide
insight into which patients are better surgical candidates.
There is a recently established and objective scoring system designed specifically to predict functional outcome
and survival in surgical patients with lung cancer metastases to the spine;29–32 this system uses markers of disease
severity (visceral metastases, multiple-level metastases,
inability to ambulate, etc.) to predict surgical outcome
and survival. Our work differs in several ways. Our work
identifies at-risk patients independent of the extent of metastases and in a nonsurgical population, and so it may be
applicable in a broader sense. Psoas size, as a surrogate
for frailty, has been verified to be predictive of morbidity
and mortality after both general9,10,17,28,40,46,56 and spine surgery.57 While our current results did not focus on morbidity and mortality after oncological surgery, we did show
that patients who were sarcopenic, as measured by a morphometric analysis of psoas size, had decreased survival.
This morphometric parameter can be applied in conjunction with other classification criteria to help guide surgical
decision-making. An observation of small psoas size and
risk of shorter survival could be useful in determining if a
patient is unfit for surgery.
The use of the vertebral body measurement to successfully normalize body habitus has been performed in
trauma patients,8 as well as in the assessment of peripheral vascular disease,48 with mixed results. Its current application—to predict mortality in oncological patients—is
novel. The impetus for finding a way to normalize each
Neurosurg Focus Volume 41 • August 2016
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TABLE 3. Overall survival and psoas size*
Variable
Total psoas tertiles
Lowest
Middle
Highest
Mean psoas tertiles
Lowest
Middle
Highest
Total psoas
Less than median
Greater than median
Mean psoas
Less than median
Greater than median
Lt psoas tertiles
Lowest
Middle
Highest
Lt psoas†
Lowest
Middle & highest
Rt psoas tertiles
Lowest
Middle
Highest

N

Median Days of Survival (95% CI)

HR (95% CI)

p Value

55
57
55

157 (107–204)
133 (102–230)
280 (191–356)

1.38 (0.94–2.02)
1.28 (0.87–1.88)
1.07 (0.74–1.57)

0.10 (1 vs 3)
0.202 (2 vs 3)
0.71 (1 vs 2)

57
53
58

173 (115–204)
127 (101–237)
270.5 (191–337)

1.34 (0.92–1.95)
1.21 (0.83–1.79)
1.10 (0.75–1.62)

0.124 (1 vs 3)
0.323 (2 vs 3)
0.613 (1 vs 2)

84
83

146 (115–186)
253.5 (179–302)

1.43 (1.05–1.94)
Reference

0.025

83
85

146 (115–186)
253 (174–302)

1.42 (1.04–1.94)
Reference

0.026

55
57
56

139 (91–185)
164 (115–269)
263 (191–337)

1.65 (1.12–2.42)
1.10 (0.75–1.61)
1.50 (1.02–2.20)

0.011 (1 vs 3)
0.636 (2 vs 3)
0.038 (1 vs 2)

55
113

139 (91–185)
222 (164–288)

1.57 (1.13–2.20)
Reference

0.007

55
56
56

173 (115–214)
136 (102–211)
276 (191–337)

1.39 (0.95–2.03)
1.29 (0.88–1.90)
1.07 (0.73–1.53)

0.094 (1 vs 3)
0.187 (2 vs 3)
0.723 (1 vs 2)

* Boldface type indicates statistical significance.
† First tertile versus second and third tertiles.

patient comes from the observation that patients who have
a small body habitus may not be sarcopenic, and would be
falsely classified as more frail by measuring lean muscle
mass alone without normalization. The vertebral body, in
a nonpathological state, maintains its size independent of
age.34 Because the origin of the psoas muscle size is on the

Fig. 1. Kaplan-Meier survival curve of total psoas size using median as
the cutoff point.
4

transverse process of the spine, it is intuitive that a normal
psoas muscle size should be in proportion to the size of the
vertebral body. Calculating a ratio between psoas size and
vertebral body size could provide a more accurate measurement of sarcopenia.
It is important to note that we observed a statistically
significant relationship with survival when looking at total

Fig. 2. Kaplan-Meier survival curve of left psoas tertiles.
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TABLE 4. Comparison of overall survival and psoas size to vertebral body ratio*
Variable
Ratio of total psoas to vertebral body area†
Lowest tertile
Middle & highest tertile
Ratio of lt psoas to vertebral body area†
Lowest tertile
Middle & highest
Ratio of rt psoas to vertebral body area
Lowest tertile
Middle tertile
Highest tertile

N

Median Days of Survival (95% CI)

HR (95% CI)

56
111

138.5 (83–191)
211 (168–288)

1.49 (1.07–2.07)
Reference

0.017

56
112

135 (85–168)
216.5 (179–280)

1.47 (1.06–2.04)
Reference

0.021

153 (99–214)
191 (133–288)
228 (124–302)

1.14 (0.78–1.67)
1.05 (0.72–1.54)
1.09 (0.74–1.68)

0.489 (1 vs 3)
0.798 (2 vs 3)
0.665 (1 vs 2)

57
53
57

p Value

* Boldface type indicates statistical significance.
† First tertile versus second and third tertiles.

psoas size, mean psoas size, and left psoas size, but not
for the right psoas. These results were maintained even
after internal normalization with vertebral body size. On
closer analysis of our previous results predicting morbidity after lumbar spine surgery, 57 we also found that the
right psoas size did not provide statistical significance, but
total psoas size, mean psoas size, and left psoas size did.
In coordination, these two findings suggest that this observation may be a reflection of reality, whereas the left
psoas muscle may be a better indicator of sarcopenia or
frailty. To our knowledge, this is the first time that this
phenomenon has been identified in the psoas size morphometric literature. We are unable to identify a plausible
rationale at this moment, although we hypothesize that
left cerebral hemispheric dominance causes attenuation of
right-sided sarcopenia due to the more frequent use of that
side. Ultimately, further and more comprehensive studies
are required to explore this finding to definitively conclude
whether this observation is a true reflection of the general
population.
Our study illustrates that morphometric analysis of
psoas size is predictive of survival in patients with lung
cancer metastasis to the spine. These findings have potential applications to oncology as well as neurosurgery. Lung

cancer is common and the leading cause of cancer death
in the world.54 The 5-year survival rate for patients with
lung cancer is poor—only 17% of patients in all stages of
the disease—with only a 2% 5-year survival rate for patients with Stage IV cancer.15 All patients in our cohort had
Stage IV lung cancer, given that all had distant metastases
to the spine.36 From an oncological perspective, there are
treatments available at this stage of lung cancer, but current guidelines recommend basing treatment strategies on
a patient’s performance status.47 To date there are no studies that directly compare performance status with frailty.
However, it has been reported that frail patients may have
poor performance status, but a poor performance status
does not always indicate frailty.12,43 Our results suggest that
analytical morphometrics as a measurement of frailty can
be predictive of survival in patients with lung cancer. The
ultimate utility of this finding, which can only be achieved
after further testing and validation, would be to use psoas
size to guide oncological treatment by identifying those
patients who are better suited for aggressive interventions.
The chief limitation of our study is its retrospective nature. While the electronic medical record is robust, we are
unable to account for any hidden bias associated with retrospective studies. Prospective multicenter studies would
be necessary to further validate our findings.

Conclusions

Morphometric analysis of psoas size can be used to
predict survival in patients with lung cancer metastases to
the spine. With further work and validation, this information could be used to select patients who are appropriate
candidates for surgery and for the tailoring of oncological
treatment regimens. Further research is needed to confirm
these results and to see if these methodologies can be applied to other cancer histologies.
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